Donald A. Kalkofen - Feb 15, 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role: Chief Financial Officer
Signature: /s/ Donald A. Kalkofen
Stock symbol: PTGX
Transactions as of: Feb 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/17/2022, 06:26 PM
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTGX	Common Stock	Award	$0	+7.5K	+68.05%	$0.00	18.5K	Feb 15, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTGX	Stock Option (right to buy)	Award	$0	+45K		$0.00	45K	Feb 15, 2022	Common Stock	45K	$28.73	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
F2	Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
F3	The stock option vests in 48 equal monthly installments following the date of grant.